Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $17.00 by Analysts at The Goldman Sachs Group

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target cut by The Goldman Sachs Group from $19.00 to $17.00 in a research report released on Wednesday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 6th. Citigroup increased their target price on Ultragenyx Pharmaceutical from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, September 18th. HC Wainwright dropped their price target on shares of Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, September 3rd. Wedbush cut their price target on shares of Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, UBS Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, October 15th. They set a “neutral” rating and a $16.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $30.47.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $17.16 on Wednesday. The company has a market cap of $1.69 billion, a PE ratio of -3.31 and a beta of 0.37. The business has a 50-day simple moving average of $16.45 and a two-hundred day simple moving average of $22.78. Ultragenyx Pharmaceutical has a fifty-two week low of $12.73 and a fifty-two week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The business had revenue of $173.00 million during the quarter, compared to analyst estimates of $182.49 million. During the same quarter in the previous year, the firm posted ($1.81) EPS. The business’s revenue was up 8.2% on a year-over-year basis. On average, sell-side analysts predict that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the sale, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. This represents a 7.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock worth $127,561 over the last three months. Insiders own 5.20% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in RARE. Parallel Advisors LLC lifted its position in Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares during the period. Sterling Capital Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 102.4% in the 3rd quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,252 shares during the last quarter. Leonteq Securities AG grew its stake in shares of Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,333 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Ultragenyx Pharmaceutical by 662.9% in the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,001 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 573.0% in the first quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,845 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability outlook. It also said expense reductions are expected to cut 2027 R&D spending by at least 50% versus 2025, and it has agreements to sell two priority review vouchers for a combined $413 million. The company also reported FDA approval of GENGLYCOS and FAYUVI in the third quarter. Company earnings release
• Neutral Sentiment: Analyst actions were mixed. TD Cowen raised its target to $19 and kept a Buy rating; Canaccord cut its target to $34 but retained Buy. Morgan Stanley raised its target to $22 with an Equal Weight rating, while Goldman Sachs and Wedbush lowered targets to $17 and $22, respectively, and kept neutral ratings. Analyst ratings
• Negative Sentiment: Third-quarter revenue was $173 million, up 8.2% year over year but below the $182.49 million consensus. The $1.16-per-share loss also missed estimates of $1.10. A Seeking Alpha analysis additionally flagged reliance on CRYSVITA, limited contributions from newer launches, and pipeline setbacks; it argued the profitability pivot depends heavily on deep R&D cuts. Seeking Alpha analysis

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.